This is early preclinical data with no human proof-of-concept — the stock may see a short-term speculative pop but lacks a catalyst for sustained re-rating. Monitor for IND filing or partnership announcements as the next meaningful milestone.
Price Chart
Executive Summary
Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/MafA) presented at the 2026 ASGCT Annual Meeting. The study in Type 2 diabetic mouse models showed reversal of hyperglycemia, improved beta-cell function, and increased mature insulin granules at four weeks post-treatment. This is early-stage preclinical data with no human clinical trial results or financial figures disclosed.
Key Facts
- Preclinical data presented May 13, 2026 at ASGCT Annual Meeting in Boston
- GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in Type 2 diabetic mouse models
- Treatment improved beta-cell function, increased mature insulin granules, and shifted beta-cells toward a more mature state
- Delivery method (endoscopic retrograde cholangiopancreatography) is technically translatable to humans
- No human clinical trial data, financial figures, or regulatory milestones disclosed in this filing
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Preclinical results may not translate to human clinical trials
- Company has going concern risk and needs additional capital (noted in forward-looking statements)
- No timeline provided for clinical development of GPX-002
- Micro-cap with $9M market cap — high volatility and low liquidity risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016883 |
| Document: 0001437749-26-016883-index-headers.html | 0001437749-26-016883 |
| Document: 0001437749-26-016883-index.html | 0001437749-26-016883 |
| Document: 0001437749-26-016883.txt | 0001437749-26-016883 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $2.05 | awaiting T+60 | — | $1.81 (−11.71%) |
Aug 18, 2026 9w ago | 8-K | $3.95 | awaiting T+60 | — | $1.81 (−54.18%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.81 (−61.89%) |
Jul 14, 2026 14w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.81 (−290.76%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.81 (+229.03%) |
May 26, 2026 21w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.81 (−89.34%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.81 (−90.44%) |
Apr 28, 2026 25w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.81 (−91.11%) |
Apr 21, 2026 26w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.81 (−92.45%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.81 (−9.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers